New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
10:27 EDTCANFCan-Fite CF102 approved for compassionate use in Israel
Can-Fite BioPharma announced that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. FDA for CF102 in the treatment of advanced hepatocellular carcinoma.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
08:45 EDTCANFCan-Fite BioPharma CF101 has major catalysts, says Roth Capital
Subscribe for More Information
07:14 EDTCANFCan-Fite BioPharma initiated with a Buy at H.C. Wainwright
Subscribe for More Information
07:08 EDTCANFCan-Fite BioPharma sees announcing data for Phase II/III psoriasis trial in 1Q15
Can-Fite BioPharma announced several upcoming and near-term milestones on its CF101 and CF102 indications for liver cancer, rheumatoid arthritis, psoriasis, glaucoma and the development of a commercial biomarker blood test kit for the A3 adenosine receptor. For Q4, the company is planning Phase III trials for CF101 for rheumatoid arthritis following the release of positive Phase II study results. Also in Q4, for CF102, patient enrollment has commenced for a Phase II trial in Israel, Europe and the U.S. for the treatment of patients with advanced liver cancer as a second line therapy. In 1Q15, for CF101, the company plans to announce data for Phase II/III trial for psoriasis with 300 patients for which Can-Fite has already received positive interim data from the first 100 patients. Also for CF101, in Q2/Q3 2015, the company plans to announce data for the Phase II study for glaucoma with 88 patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use